Product Description
Human serum albumin fused to the N-terminus of growth hormone (Sourced from: https://chem.nlm.nih.gov/chemidplus/rn/1613273-96-3)
Mechanisms of Action: Growth Hormone Analogue
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hypopituitarism|Pituitary Diseases|Dwarfism, Pituitary|Deficiency Diseases
Phase 2: Hypopituitarism|Dwarfism, Pituitary|Pituitary Diseases|Deficiency Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2014-002736-13 | P3 |
Terminated |
Hypopituitarism |
2017-08-19 |
|
| TV1106-IMM-20001 | P2 |
Terminated |
Hypopituitarism|Dwarfism, Pituitary |
2016-04-30 |
32% |
| 2013-004468-69 | P2 |
Terminated |
Hypopituitarism |
2016-04-29 |
|
| TV1106-IMM-30022 | P3 |
Terminated |
Pituitary Diseases|Dwarfism, Pituitary|Deficiency Diseases|Hypopituitarism |
2016-02-29 |
95% |